SPRENGELER, PAUL A.,REICH, SIEGFRIED H.,ERNST, JUSTIN T.,WEBBER, STEPHEN E.,SHAGHAFI, MIKE,MURPHY, DOUGLAS,TRAN, CHINH
申请号：
CA3002877
公开号：
CA3002877A1
申请日:
2016.10.28
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript "n" are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
